EUVIMEDEUVIMED entdecken
Crossref

Real‐World Outcomes of Patients Treated With Neoadjuvant Imatinib for Locally Advanced, Recurrent and Limited Metastatic Gastrointestinal Stromal Tumour in an Australian Cancer Training Network

Amy E Smith iD, Karan Gupta, Florian Honeyball, Peter Grimison, Philip Beale

Asia-Pacific Journal of Clinical Oncology · 2025

DOI: 10.1111/ajco.70034 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Asia-Pacific Journal of Clinical Oncology, 2025. Verfasst von Amy E Smith und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Concord Repatriation and General Hospital, Sydney, Australia. Hauptthemen laut MEDLINE: Imatinib Mesylate, Gastrointestinal Stromal Tumors, Neoplasm Recurrence, Local, Antineoplastic Agents. Die Arbeit nennt 19 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Imatinib for palliative and adjuvant treatment of gastrointestinal stromal tumours (GISTs) with common KIT mutations has been revolutionary. For patients with locally advanced, limited metastatic or recurrent disease, neoadjuvant imatinib may downstage the tumour, enabling surgery with curative intent; however, the optimal duration of neoadjuvant imatinib is unknown.

Methods

We conducted a retrospective review of patients with locally advanced, limited metastatic and recurrent GIST treated with neoadjuvant imatinib prior to consideration of surgical resection in the period 2012–2024 at three cancer centres in NSW, Australia. Baseline and outcome data were collected. The primary endpoint was the progression‐free survival (PFS).

Results

A total of 30 patients were identified with 38 instances of primary locally advanced, recurrent or limited metastatic disease. The median per‐patient duration of neoadjuvant imatinib was 7.8 months (range 2.9–14.9 months), and the median per‐episode duration of neoadjuvant imatinib was 9.1 months (range 3.0–27.4 months). Maximum radiological response was achieved at 3.8 months for primary tumours and 6.7 months for recurrent tumours. Partial response occurred in 77% and progression in 0%. Of the 25 patients with available data, 96% were symptomatic, and 89% reported early symptomatic benefit from imatinib within 1 month. Complete surgical resection occurred in 58% of all episodes of neoadjuvant treatment. The estimated PFS rates at 2 and 5 years were 84% and 55% respectively. Overall survival rates were 84% at both 2 and 5 years.

Conclusions

Neoadjuvant imatinib provided effective symptomatic and radiological responses in patients with locally advanced, limited metastatic or recurrent GIST. A duration of 3–6 months treatment for primary tumours and 6–12 months for recurrent disease appears sufficient for most patients. Mutational profile analysis is of particular value for patients who do not have early symptomatic benefit, have poor radiological response or have recurrent disease.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Imatinib MesylateGastrointestinal Stromal TumorsNeoplasm Recurrence, LocalAntineoplastic AgentsGastrointestinal NeoplasmsHumansMaleFemaleMiddle AgedRetrospective StudiesNeoadjuvant TherapyAgedAdultAustraliaAged, 80 and overTreatment Outcome

Stichwörter der Autor:innen

mutation profilingpre‐operativerecurrencesarcomatyrosine kinase inhibitors

Substanzen

Imatinib MesylateAntineoplastic Agents

Autor:innen und Institutionen

  • Department of Medical Oncology, Concord Repatriation and General Hospital, Sydney, Australia.
  • Department of Medical Oncology, Chris O'Brien Lifehouse, Sydney, Australia.
  • Western Cancer Centre, Dubbo Base Hospital, Dubbo, Australia.
  • School of Rural Health, University of Sydney, Sydney, Australia.
  • Sydney Medical School, University of Sydney, Sydney, Australia.

ORCID-Profile: Amy E Smith

Zitieren

APA

Smith, A. E., Gupta, K., Honeyball, F., Grimison, P., & Beale, P. (2025). Real‐World Outcomes of Patients Treated With Neoadjuvant Imatinib for Locally Advanced, Recurrent and Limited Metastatic Gastrointestinal Stromal Tumour in an Australian Cancer Training Network. Asia-Pacific Journal of Clinical Oncology. https://doi.org/10.1111/ajco.70034

Vancouver

Smith AE, Gupta K, Honeyball F, Grimison P, Beale P. Real‐World Outcomes of Patients Treated With Neoadjuvant Imatinib for Locally Advanced, Recurrent and Limited Metastatic Gastrointestinal Stromal Tumour in an Australian Cancer Training Network. Asia-Pacific Journal of Clinical Oncology. 2025. doi:10.1111/ajco.70034

BibTeX
@article{Smith2025,
  author = {Smith, Amy E and Gupta, Karan and Honeyball, Florian and Grimison, Peter and Beale, Philip},
  title = {Real‐World Outcomes of Patients Treated With Neoadjuvant Imatinib for Locally Advanced, Recurrent and Limited Metastatic Gastrointestinal Stromal Tumour in an Australian Cancer Training Network},
  journal = {Asia-Pacific Journal of Clinical Oncology},
  year = {2025},
  doi = {10.1111/ajco.70034}
}
Kostenlos starten →